Elliott, M.J., Maini, R.N., Feldmann, M., Kalden, J.R., Antoni, C., Smolen, J.S., Leeb, B., Breedveld, F.C., Macfarlane, J.D., Bijl, H. and Woody, J.N. (1994) Randomized Double-Blind Comparison of Chimeric Monoclonal Antibody to Tumor Necrosis Factor Alpha (cA2) versus Placebo in Rheumatoid Arthritis. Lancet, 344, 1105-1110.
http://dx.doi.org/10.1016/S0140-6736(94)90628-9

has been cited by the following article:

• TITLE: Additional Treatment Modality to Improve Outcomes in Myocardial Infarctions and Strokes

  AUTHORS: Simon Skurkovich, Boris Skurkovich

  KEYWORDS: Neutralization of Pro-Inflammatory Cytokines, Myocardial Infarction, Stroke

  JOURNAL NAME: Journal of Immune Based Therapies, Vaccines and Antimicrobials, Vol.3 No.2, April 17, 2014

  ABSTRACT: In 1974, in Nature, we hypothesized that removal of cytokines can be effective in the treatment of certain inflammatory diseases, e.g., rheumatoid arthritis (RA). We call this approach anticytokino-therapy. Later it was shown that neutralization of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), interferon alpha (IFN-α), interferon gamma (IFN-γ), and interleukin 6 (IL-6), leads to a good therapeutic effect. Anticytokinotherapy is currently used around the world for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, and other Th-1-mediated inflammatory diseases. Pro-inflammatory cytokines have also been found in other conditions (myocardial infarctions, strokes, chronic pain syndromes, etc.). This leads us to believe that hyper- production of pro-inflammatory cytokines forms a basis of a variety of pathological conditions and represents a uniform response of the organism to a wide variety of insults in any part of the body. Thus, we propose to add monoclonal antibodies to (or other blockers of) pro-inflammatory cytokines to the treatment regimens for myocardial infarctions, strokes, and possibly other Th-1-mediated diseases.